

ASX ANNOUNCEMENT

Appendix 4C – Quarterly Cash Flow Report

Highlights for the quarter ended 31st December 2017

- **Share rights issue raises \$1,370k October 2017**
- **Cash balance as of 31st December, \$799k**
- **\$1,370k cash received if all options exercised 31st January 2018**
- **\$1,370k cash received if all options exercised 31st May 2018**
- **Appointment of Navigant Capital Advisors LLC**
- **Revolutionary PeriCoach® technique scoring demonstrates game changing success.**

29th January 2018: Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® system and the AutoStart® and AutoFlush infusion system technologies, has today released its Appendix 4C - Quarterly Cashflow report for period ending 31st December 2017.

Receipts from sales of PeriCoach in Analytica's key markets of Australia, the UK and the US totalled \$20k, with extremely limited commercial activity occurring. The marketing activity is focused on recruitment for data collection and feature development. Research & development expenditure was \$376k, dominated by expenditure on the PeriCoach "big data" project, the largest and most comprehensive pelvic floor muscle exercise database in the world. \$299k was incurred on staff costs. Administration costs of \$221k included one off costs of \$143k incurred on partnering expenditure. It is anticipated that expenditure will be lower this quarter.

During the quarter, the company received \$1,370k of capital.

The Board and management appreciate the confidence of our major shareholders for supporting this rights issue. These funds are being deployed to continue the development of the PeriCoach System and advance negotiations with potential partners.

On the 31st of January the options issued on 17th October 2017 at \$0.005 expire. If fully subscribed this would contribute \$1,370k in additional capital. A further exercise of options in May 2018 at \$0.005, if fully subscribed, would contribute a further \$1,370k.

An application for research and development tax incentive has been finalised to entitle the company to claim an estimate of \$850k tax refund for research and development expenditure this last financial year. The company also has access to a \$400k loan facility. Directors are monitoring capital requirements to ensure the company has adequate cash to continue development and undertake partnering negotiations of the PeriCoach and the AutoFlush and AutoStart burette technologies. The Company continues to have the financial support of its major shareholders.

For the last 10 months Analytica has been building a data room to support the outreach to prospective partners. The next step in the commercialisation process was the appointment, announced 6th November, of New York based investment bank, Navigant Capital Advisors LLC, to run the process for the sale of the



PeriCoach, AutoStart and AutoFlush. Navigant has a strong record in commercialising medical devices and has over 5,500 professionals and 1,900 subject matter experts.

PeriCoach is a registered medical device, built on the foundations of a data collection and analysis system. The system provides opportunity for new insights into management and motivation of the conservative treatment pathway for female pelvic floor disorders. This core capability is the driver for the pursuit of clinical evidence as well as development of enhanced functionality of the PeriCoach system. Continued investment in real world data-gathering tools to increase the sophistication of analysis of user behaviour and pelvic health information is the cornerstone of company strategy.

The PeriCoach version 3 system, combined with the “big data” analysis project has enabled unique insights into pelvic floor exercise techniques. The revolutionary technique scoring system built into V3 uses sophisticated proprietary algorithms to provide women with immediate biofeedback, allowing them to self-correct.

The fundamental principle of pelvic floor exercise is that if women do their pelvic floor exercise regularly and correctly, they will improve their strength and control. Early PeriCoach V3 data shows that 53% of women do not exercising correctly when they start their programme. Ordinarily this would lead to poor progress and decreased motivation and giving up. With the PeriCoach V3, the data shows that many PeriCoach patients are using the biofeedback to correct their own technique, in the privacy of their own home. This is important because Analytica data shows that 62% of our patients would not seek help about their incontinence from a clinician and would consequently never receive guidance on technique correction.

Analytica’s clinical trial completed last year reported significant improvements in quality of life and sexual function using the PeriCoach V2. The vastly superior PeriCoach V3 with the addition of bladder diary, quality of life feedback, a structured 8-week challenge exercise programme, and technique feedback is making a huge improving in women’s lives.

Analytica’s data analysis project is ongoing and is continually providing other exciting insights into strength, control and patient outcomes. Analytica expects these unique insights to provide world-leading changes in the efficacy of pelvic floor exercise.

As outlined in the Chairman’s address to the Annual General Meeting in November 2017, Analytica is achieving its goals set out at the Annual General meeting 2016 of being deal-ready. This quarter demonstrates further strong progress to the Company strategy; build a product that is best in class, gather evidence that the product performance is exceptional, and actively pursue partnering opportunities.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:





About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia and New Zealand, UK and Ireland, and in the USA.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Analytica Ltd

ABN

12 006 464 866

Quarter ended ("current quarter")

December 2017

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities			
1.1 Receipts from customers	20	40	
1.2 Payments for			
(a) research and development	(376)	(713)	
(b) product manufacturing and operating costs	(11)	(12)	
(c) advertising and marketing	(18)	(70)	
(d) leased assets			
(e) staff costs	(299)	(575)	
(f) administration and corporate costs	(221)	(340)	
1.3 Dividends received (see note 3)			
1.4 Interest received	3	5	
1.5 Interest and other costs of finance paid			
1.6 Income taxes paid			
1.7 Government grants and tax incentives			
1.8 Other (provide details if material)			
1.9 Net cash from / (used in) operating activities	(902)	(1,665)	
2. Cash flows from investing activities			
2.1 Payments to acquire:			
(a) property, plant and equipment	(3)	(3)	
(b) businesses (see item 10)			
(c) investments			

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
	(d) intellectual property		
	(e) other non-current assets		
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment		
	(b) businesses (see item 10)		
	(c) investments		
	(d) intellectual property		
	(e) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	Net cash from / (used in) investing activities	(3)	(3)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares	1,370	1,370
3.2	Proceeds from issue of convertible notes		
3.3	Proceeds from exercise of share options		
3.4	Transaction costs related to issues of shares, convertible notes or options	(110)	(115)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	Net cash from / (used in) financing activities	1,260	1,255

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	444	1,212
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(902)	(1,665)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(3)	(3)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,260	1,255

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of quarter	799	799

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	799	799
5.2 Call deposits		
5.3 Bank overdrafts		
5.4 Other (provide details)		
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	799	799

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

**Current quarter
\$A'000**

114
0

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

**Current quarter
\$A'000**

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	400	0
8.2 Credit standby arrangements		
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		
Capital raising received \$1,334k in October.		

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	200
9.2 Product manufacturing and operating costs	45
9.3 Advertising and marketing	45
9.4 Leased assets	
9.5 Staff costs	250
9.6 Administration and corporate costs	150
9.7 Other (provide details if material)	
9.8 Total estimated cash outflows	690

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: Date:
(Director)

Print name: R. Mangelsdorf

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.